The Chinese government on Saturday ordered the release of people detained over a host of coronavirus-related incidents, a day ahead of Beijing's plan to scrap its three-year-old stringently implemented zero-Covid policy.
Vice President Hamid Ansari on Thursday visited Angkor Wat days after India allayed Cambodian concerns over reports of building of a replica of the world heritage site in Bihar.
Describing Central Asia as India's "extended neighbourhood", Doval said New Delhi accords "highest priority" to this region, adding Afghanistan is an important issue "concerning all of us".
Prime Minister Narendra Modi will join several global leaders to pay tributes to Japan's slain former prime minister Shinzo Abe at his state funeral in Tokyo on Tuesday.
The Enforcement Directorate has issued fresh summons to Jharkhand Chief Minister Hemant Soren to appear before it in Ranchi on November 17 for questioning in a money laundering case linked to alleged illegal mining in the state, official sources said Wednesday.
Will G20 showcase an India that is inclusive, culturally rich, diverse and tolerant, asks Ramesh Menon.
'We are receiving a steady stream of interest from well-established foreign universities.'
ndependent of the political fallout, which Stalin has sought to arrest through the withdrawal of the measures as fast as they were introduced, there are concerns about the way those decisions came to be taken, without adequate application of mind, not in official terms but in political and electoral contexts, points out N Sathiya Moorthy.
Other than Snapdeal, the four markets are Tank Road in Delhi, Heera Panna in Mumbai, Kidderpore in Kolkata and Millennium Centre in Aizawl. Snapdeal, one of India's largest e-commerce platforms, is known as a place to purchase counterfeit watches and shoes.
Mathew Martoma, a former SAC Capital portfolio manager, faces 20 years in prison for securities fraud and five years for conspiracy
Failure to recognise the threat of India's IP abuse is a major step back: Congressman Orrin Hatch.
Reinvent and innovate will be the key mantra for the Indian pharma industry in the New Year as the 'pharmacy of the world' looks to move from volume to value leadership, amid emerging challenges of inflation and pricing pressures in the global markets. While R&D investment, market competitiveness, regulatory scrutiny, and domestic price regulations are expected to shape the growth of generics and injectable products, concerns such as price control and customs duties on medical equipment will continue to bother the healthcare industry in 2023. The industry believes that in view of India's G20 Presidency, digital health innovation, achieving universal health coverage, improving healthcare infrastructure and delivery will continue to be the key driving factors in 2023.
The Jharkhand Mukti Morcha leader had asked the ED to advance the date of appearance to November 16, which has not been agreed to by the agency, they said.
Communications between the USTR and the world's most powerful pharmaceutical and trade lobbying groups reveal that many raised concerns about India's push to exempt Covid vaccines from intellectual property.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances